We come together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease.
On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies.
We continuously seek to understand the diverse perspectives of rare patients to courageously forge new paths that can make a difference in their lives and provide hope for today and tomorrow.
We are committed to broad access for our FDA-approved therapies, and we provide personalized clinical support services through the Total Care Hub.
We are dedicated to staying informed and engaged on topics that may impact the rare disease community, featuring community members and sharing what we learn. Find info at our Pathfinder.
SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2020 financial results and provided a corporate update.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), EveryLife Foundation for Rare Diseases, Global Genes, and rare disease advocates and patients worldwide in recognizing February 28 as Rare Disease Day 2021.
On February 23, 2021, the Black Women’s Health Imperative (BWHI) held the first public meeting of the Rare Disease Diversity Coalition (RDDC) with more than 200 rare disease community members joining together to endorse an ambitious platform of 10 initiatives to achieve tangible solutions to address issues, including delays in diagnosis and treatment for diverse patients. We’re proud to work closely with the leaders of the BWHI to spearhead the formation of the RDDC.
On February 23, 2021, the nonprofit organization RARE-X announced plans to expand its work helping patient groups collect structured, standardized research-ready data that will better support the development of future treatments. This foundational work is made possible through a funding commitment from Travere Therapeutics.
Valarie describes her family’s journey with baby Delila who has Alagille syndrome.
Retrophin is now Travere Therapeutics.
© 2021 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
Meet Gisela
Advocacy, Stories & Insights“How do you know you have IgA nephropathy?” asked Gisela’s nephrologist skeptically. Gisela was 30 years old, talking to a nephrologist for the first time in a decade. Read and watch her story.